The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

[1]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[2]  F. Ingegnoli,et al.  COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.

[3]  Zhigang Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[4]  E. Rubin,et al.  Covid-19 — The Search for Effective Therapy , 2020, The New England journal of medicine.

[5]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[6]  X. Bian,et al.  [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[7]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[8]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[9]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[10]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[11]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019 , 2020, medRxiv.

[12]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[13]  Suxin Wan,et al.  Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.

[14]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[15]  R. Schneider,et al.  Systemic Juvenile Idiopathic Arthritis , 2020, Definitions.

[16]  Feng Li,et al.  Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity , 2020, Emerging microbes & infections.

[17]  Wei Zhang,et al.  Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes , 2020, Emerging microbes & infections.

[18]  N. Berliner,et al.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. , 2019, Blood.

[19]  S. Ohlman,et al.  Anakinra in children and adults with Still’s disease , 2019, Rheumatology.

[20]  B. Trapnell,et al.  Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors , 2019, Arthritis & rheumatology.

[21]  Y. F. Ibrahim,et al.  Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein , 2019, Inflammopharmacology.

[22]  M. Borca,et al.  The Role of Interleukin 6 During Viral Infections , 2019, Front. Microbiol..

[23]  K. Nichols,et al.  The Immunology of Macrophage Activation Syndrome , 2019, Front. Immunol..

[24]  R. Schneider,et al.  Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. , 2018, Clinical and experimental rheumatology.

[25]  Y. Shoenfeld,et al.  Eppur Si Muove: ferritin is essential in modulating inflammation , 2018, Clinical and experimental immunology.

[26]  A. Grom.  Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome: The Importance of Timely Clinical Differentiation. , 2017, The Journal of pediatrics.

[27]  J. Tran van Nhieu,et al.  Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury , 2017, Respiratory Research.

[28]  Shun-Hua Chen,et al.  IL-6 ameliorates acute lung injury in influenza virus infection , 2017, Scientific Reports.

[29]  F. De Benedetti,et al.  Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome , 2017, Pediatric Rheumatology.

[30]  C. Wouters,et al.  Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options , 2016, British journal of haematology.

[31]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[32]  M. Hatano,et al.  Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis , 2015, Respiratory Research.

[33]  T. Morio,et al.  Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab , 2015, The Journal of Rheumatology.

[34]  Y. Shoenfeld,et al.  sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia , 2014, Immunologic Research.

[35]  G. Marseglia,et al.  A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. , 2014, Autoimmunity reviews.

[36]  Anuh T. George,et al.  Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis , 2014, The Journal of Immunology.

[37]  G. D'Ario,et al.  Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model , 2014, Pediatric Rheumatology.

[38]  S. Amselem,et al.  How should we approach classification of autoinflammatory diseases? , 2013, Nature Reviews Rheumatology.

[39]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[40]  Y. Shoenfeld,et al.  The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome , 2013, BMC Medicine.

[41]  Rhea Bhargava,et al.  Intratracheal IL-6 Protects against Lung Inflammation in Direct, but Not Indirect, Causes of Acute Lung Injury in Mice , 2013, PloS one.

[42]  C. Wouters,et al.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[43]  A. Martini.  Systemic juvenile idiopathic arthritis. , 2012, Autoimmunity reviews.

[44]  Ali Danesh,et al.  Lack of Innate Interferon Responses during SARS Coronavirus Infection in a Vaccination and Reinfection Ferret Model , 2012, PloS one.

[45]  Michael G. Katze,et al.  Into the Eye of the Cytokine Storm , 2012, Microbiology and Molecular Reviews.

[46]  Jonathan G. Rud,et al.  Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung , 2012, Mucosal Immunology.

[47]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.

[48]  A. Martini,et al.  An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis , 2011, The Journal of Rheumatology.

[49]  S. Gupta,et al.  Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy , 2010, Expert review of clinical immunology.

[50]  S. Mahajan,et al.  SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro , 2009, Virus Research.

[51]  A. Ghaffar,et al.  Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[52]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[53]  E. Behrens.  Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? , 2008, Autoimmunity reviews.

[54]  Wei Wang,et al.  Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway , 2007, Virus Research.

[55]  P. Palese,et al.  Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists , 2006, Journal of Virology.

[56]  Dennis McGonagle,et al.  A Proposed Classification of the Immunological Diseases , 2006, PLoS medicine.

[57]  J. Scheller,et al.  Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer , 2006, Scandinavian journal of immunology.

[58]  H. Tsutsumi,et al.  Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections† , 2006, Journal of medical virology.

[59]  J. Scheller,et al.  IL-6 transsignaling: the in vivo consequences. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[60]  C. Peters,et al.  Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) , 2004, Virology.

[61]  A. Mencacci,et al.  Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. , 2001, The Journal of infectious diseases.

[62]  C. Dinarello.  Targeting interleukin 18 with interleukin 18 binding protein , 2000, Annals of the rheumatic diseases.

[63]  S. Kaufmann,et al.  Copyright © 1997, American Society for Microbiology Lethal Tuberculosis in Interleukin-6-Deficient Mutant Mice , 1997 .

[64]  T. van der Poll,et al.  Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. , 1997, The Journal of infectious diseases.

[65]  A. Martini,et al.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. , 1996, The Journal of pediatrics.

[66]  F. Stentz,et al.  Clinical Investigations in Critical CareInflammatory Cytokines in the BAL of Patients With ARDS: Persistent Elevation Over Time Predicts Poor Outcome , 1995 .

[67]  F. Stentz,et al.  Clinical Investigations in Critical CarePersistent Elevation of Inflammatory Cytokines Predicts a Poor Outcome in ARDS: Plasma IL-1β and IL-6 Levels Are Consistent and Efficient Predictors of Outcome Over Time , 1995 .

[68]  A. Martini,et al.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[69]  R. Tattersall,et al.  Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment , 2019, Rheumatology.

[70]  S. Rose-John,et al.  Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer. , 2018, Methods in molecular biology.

[71]  Alberto Mantovani,et al.  Macrophage activation and polarization. , 2008, Frontiers in bioscience : a journal and virtual library.

[72]  Paul Landais,et al.  Extended Report , 2022 .